Everest Group Ltd (EG) Stock News

In a comparison of two Internet-Software sector stocks, 8x8 (EGHT) emerges as the superior value option compared to Autodesk (ADSK). EGHT has a stronger Zacks Rank (#2 Buy vs #3 Hold), better valuation metrics including a forward P/E of 5.18 versus 16.81, and a Value grade of A compared to ADSK's C grade.

Rosen Law Firm has filed securities class action lawsuits against Blaize Holdings, Hyliion Holdings, and Primoris Services Corporation, alleging false statements and improper revenue recognition. Investors who purchased securities during specified class periods are encouraged to join the litigation before upcoming deadlines, with the lead plaintiff deadline for Blaize set for October 5, 2026.

Rosen Law Firm reminds investors in Cogent Communications Holdings, Inc. (NASDAQ: CCOI) who purchased stock between February 29, 2024 and May 1, 2026 of the September 21, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that defendants made materially false statements regarding optical wavelength backlog, customer demand, revenue targets, dividend sustainability, and undisclosed risks related to insider stock pledging activities.

A securities class action lawsuit has been filed against Regeneron Pharmaceuticals over allegations that the company made false and misleading statements regarding a Phase 3 clinical trial of Fianlimab for melanoma treatment. The trial failed to reach statistical significance on its primary endpoint, causing an $11 billion market cap loss. Investors claim Regeneron concealed flawed statistical assumptions and slow event rates while expressing confidence in the trial's success. The lead plaintiff deadline is September 14, 2026.

Rosen Law Firm is notifying investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) of a securities class action lawsuit with a September 22, 2026 lead plaintiff deadline. The lawsuit alleges that PROCEPT made materially false statements regarding its sales practices, including use of undisclosed discount programs that artificially inflated handpiece unit sales and revenues, created excess inventory of over 10,000 units, and made unachievable 2025 guidance. Investors with losses exceeding $100,000 are encouraged to seek counsel.

Pomerantz Law Firm has filed class action lawsuits against Regeneron Pharmaceuticals, Capricor Therapeutics, and GPGI, Inc. for alleged securities fraud. The primary focus is on Regeneron, where a Phase III clinical trial for Fianlimab-Libtayo failed to meet its primary endpoint, causing the stock to decline significantly on two separate occasions in April and May 2026. Investors with losses are urged to contact the firm by September 14, 2026, to potentially become lead plaintiffs.

Sky Blue Cinematix has been appointed as the exclusive worldwide brand-integration partner for two upcoming feature films from Tested Films: the action thriller 'Habeas Corpus' and the neo-noir romantic mystery 'Blurred', both directed by Ben Cookson. The partnership will connect international brands with these theatrical productions through in-film integration across all territories.

Phillips Edison & Company (PECO) presents a better value opportunity than Regency Centers (REG) based on Zacks Rank and Style Scores analysis. PECO holds a #2 Buy rating with a Value grade of B, while REG has a #3 Hold rating with a Value grade of D. PECO's forward P/E of 14.07 and PEG ratio of 2.02 are more favorable than REG's forward P/E of 15.49 and PEG ratio of 4.47.

Rogers and OEG Sports & Entertainment announced a 10-year extension of their strategic partnership, securing Rogers Place as the home of the Edmonton Oilers through 2036. To celebrate the arena's 10-year anniversary, Rogers is giving away over 1,500 tickets to customers throughout the season, including 300 for the Home Opener on September 29. The extension builds on an unprecedented sponsorship deal signed in 2013 and includes extensive brand placements and advertising across the arena.

Rogers and OEG Sports & Entertainment announced a 10-year partnership extension through 2036, making Rogers Place the home of the Edmonton Oilers. As part of the celebration of Rogers Place's 10th anniversary, Rogers will distribute over 1,500 tickets to customers during the season, including 300 for the home opener on September 29 against Vancouver Canucks. The partnership includes media rights through Sportsnet and various fan engagement initiatives.

Rosen Law Firm has filed a class action lawsuit against Innventure, Inc. (NASDAQ: INV) on behalf of investors who purchased securities between November 17, 2025 and August 13, 2026. The lawsuit alleges that defendants made materially false and misleading statements regarding Accelsius Holdings LLC's transformative deal with DarkNX, which allegedly was unlikely to materialize, and that revenue and cash flow targets for 2026 were overstated. Investors must move the court by October 27, 2026 to serve as lead plaintiff.

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against Alibaba Group Holding Limited. The lawsuit alleges that Alibaba made false and misleading statements regarding its control by the Chinese Ministry of Industry and Information Technology (MIIT), which would classify it as a Chinese military company under the National Defense Authorization Act, and failed to disclose ongoing distillation attacks against third-party AI models. The lead plaintiff deadline is October 5, 2026.

Rosen Law Firm is notifying investors of securities class action lawsuits against Blaize Holdings, GoDaddy Inc., and Rackspace Technology. The lawsuits allege false statements, improper revenue recognition, and misleading disclosures. Investors have until specified deadlines to join as lead plaintiffs or class members.

eGain reported Q2 2026 earnings of $0.08 per share, beating consensus estimates by 167% and surpassing revenue expectations. However, the stock has declined 29.7% year-to-date versus the S&P 500's 12% gain. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions. Meanwhile, Micron is expected to report quarterly earnings of $31.39 per share with revenues of $50.76 billion, representing significant year-over-year growth.

A securities class action lawsuit has been filed against Regeneron Pharmaceuticals for allegedly making false and misleading statements about its Phase 3 clinical trial of Fianlimab for melanoma treatment. The company reportedly failed to disclose that preliminary statistical assumptions were flawed and the primary endpoint was unlikely to be achieved. After initially expressing confidence in the trial, Regeneron altered the trial protocol in November 2025 without timely disclosure and ultimately announced on May 15, 2026 that the trial failed to reach statistical significance, resulting in an $11 billion market cap loss.

Rosen Law Firm is reminding investors who purchased Datavault AI Inc. securities between September 4, 2024 and October 30, 2025 of an important October 5, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that defendants made materially false statements regarding corporate partnerships, overstated trading activity on the Datavault Platform, and failed to disclose connections with a convicted felon, causing reputational harm.

A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) alleging that defendants made false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. Investors who purchased securities between March 9, 2026 and June 24, 2026 may be entitled to compensation. The lead plaintiff deadline is October 5, 2026.

HUTCHMED announced positive Phase III SANOVO trial results showing that ORPATHYS® (savolitinib) combined with TAGRISSO® (osimertinib) demonstrated statistically significant progression-free survival improvements and encouraging overall survival benefits in treatment-naïve patients with MET-overexpressing EGFR-mutated NSCLC in China, extending the clinical value of the combination into the first-line setting.

Rosen Law Firm is notifying investors who purchased Hertz Global Holdings (NASDAQ: HTZ) common stock between May 7, 2026 and June 23, 2026 of an important September 22, 2026 deadline to serve as lead plaintiff in a securities class action lawsuit. The lawsuit alleges that Hertz made materially false and misleading statements regarding its liquidity position, mischaracterizing market softness as transitory when it was actually recurring, and failing to disclose the need for a dilutive, distressed capital raise that would harm shareholders.

Rosen Law Firm reminds investors of the September 22, 2026 lead plaintiff deadline in a securities class action against PROCEPT BioRobotics Corporation. The lawsuit alleges that PROCEPT made materially false statements regarding its discount programs, handpiece unit sales, and revenue guidance. The company allegedly used undisclosed bulk order discounts that artificially inflated sales figures and created excess inventory of over 10,000 units, exposing the company to material operational and financial risks.

REGL is a smart beta ETF focused on mid-cap dividend aristocrats with $1.78 billion in assets. The fund has delivered 12.47% returns year-to-date and 10.97% over the past year, with a 2.17% dividend yield and 0.40% expense ratio. It carries medium risk with a beta of 0.71 and holds about 66 stocks across financials, industrials, and utilities sectors.

A comparison of Deutsche Telekom AG (DTEGY) and Swisscom AG (SCMWY) in the Diversified Communication Services sector reveals that DTEGY is more attractive for value investors. DTEGY has a Zacks Rank of #2 (Buy) with a forward P/E of 13.02 and a Value grade of A, while SCMWY has a Zacks Rank of #3 (Hold) with a forward P/E of 24.90 and a Value grade of F. DTEGY's superior valuation metrics and stronger earnings estimate revision activity make it the better choice for value-focused investors.

A securities class action lawsuit has been filed against Pentwater Capital Management LP and its CEO Matthew Halbower, alleging they orchestrated a market manipulation scheme involving Avis Budget Group stock. The defendants, holding approximately 51% economic interest in Avis, allegedly engaged in aggressive stock purchases during February 2025 to April 2026 that triggered a short squeeze, artificially inflating the stock price and benefiting their holdings. Investors who purchased Avis securities during this period may be eligible for compensation, with a September 29, 2026 deadline to serve as lead plaintiff.

Constellation Energy secured 920 megawatts of long-term power purchase agreements in Q2, including a major 176 MW contract with Walmart spanning two 15-year terms. The company also made significant progress on its Microsoft deal with NRC approval for the Crane Clean Energy Center. Constellation projects 20% annualized earnings growth through 2029, with additional upside from future contracts.

Klépierre, Europe's leading shopping mall operator, has raised its full-year 2026 guidance with EBITDA expected to reach a minimum of €1,150 million. The company demonstrated strong execution in a dynamic retail market, driving organic growth. As of July 31, 2026, the company had 286.86 million shares outstanding.

The Schall Law Firm is seeking investors to join a class action lawsuit against Regeneron Pharmaceuticals for securities fraud. The company allegedly made false and misleading statements about its Phase III Fianlimab-Libtayo study, claiming it was likely to succeed when it actually failed to demonstrate clinical differentiation from competing therapies. Investors who purchased securities between August 1, 2025 and May 15, 2026 are encouraged to participate before the September 14, 2026 deadline.

Regeneron Pharmaceuticals faces a securities class action lawsuit after failing to disclose critical information about its Phase 3 clinical trial for a melanoma treatment combination therapy. The company allegedly made false statements about trial progress while concealing that preliminary statistical assumptions were flawed and the treatment showed no meaningful differentiation over standard therapies. The trial ultimately failed to reach statistical significance, resulting in an $11 billion market cap loss. The class period covers August 1, 2025 to May 15, 2026.

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary focus is on Erasca, Inc., which allegedly made false and misleading statements about its lead oncology drug candidate ERAS-0015, claiming it was 'best-in-class' while failing to disclose improper comparisons to competitors and lacking reasonable basis. The firm is seeking lead plaintiffs with an August 10, 2026 deadline for Erasca and August 4, 2026 for PicS N.V.

A securities fraud class action lawsuit has been filed against Regeneron Pharmaceuticals for allegedly misleading investors about the success of its Phase III Fianlimab-Libtayo clinical trial. The stock dropped 6.2% on April 29, 2026, and 9.8% on May 15, 2026, after the company announced the study failed to achieve statistical significance. Investors have until September 14, 2026, to request lead plaintiff status.

Regeneron Pharmaceuticals faces a securities class action lawsuit after failing to disclose critical information about its Phase 3 clinical trial for a melanoma treatment combination therapy. The company allegedly made misleading statements about the trial's progress while concealing that preliminary statistical assumptions were flawed and the primary endpoint was unlikely to be achieved. The trial ultimately failed to reach statistical significance, resulting in an $11 billion market cap loss. The class period covers August 1, 2025 to May 15, 2026, with a lead plaintiff deadline of September 14, 2026.